Smoking and vascular risk: Are all forms of smoking harmful to all types of vascular disease?

Public Health

Volumn 127, Issue 5, 2013, Pages 435-441

  Katsiki, N ^a,b   Papadopoulou, S K ^c,d   Fachantidou, A I ^d   Mikhailidis, D P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Abdominal aortic aneurysms; Cardiovascular disease; Carotid arterial disease; Peripheral arterial disease; Smoking

Indexed keywords

CANNABINOID DERIVATIVE; CANNABIS; NICOTINE; RIMONABANT;

CARDIOVASCULAR DISEASE; HEALTH CARE; HEALTH RISK; PUBLIC HEALTH; RISK FACTOR; SMOKING;

ABDOMINAL AORTA ANEURYSM; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DYSLIPIDEMIA; HEALTH HAZARD; HEART INFARCTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; PATIENT COUNSELING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PIPE SMOKING; PRIMARY PREVENTION; RISK REDUCTION; SECONDARY PREVENTION; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; TACHYCARDIA; VASCULAR DISEASE;

AORTIC ANEURYSM, ABDOMINAL; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CORONARY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; HEMOSTASIS; HUMANS; HYPERTENSION; MARIJUANA SMOKING; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; SMOKING; TOBACCO, SMOKELESS;

CANNABIS; NICOTIANA TABACUM;

EID: 84878398250     PISSN: 00333506     EISSN: 14765616     Source Type: Journal    
DOI: 10.1016/j.puhe.2012.12.021     Document Type: Article

References (105)

1. Mazzone P., Tierney W., Hossain M., Puvenna V., Janigro D., Cucullo L. Pathophysiological impact of cigarette smoke exposure on the cerebrovascular system with a focus on the blood-brain barrier: expanding the awareness of smoking toxicity in an underappreciated area. Int J Environ Res Public Health 2010, 7:4111-4126.
2. Alberg A.J. Cigarette smoking: health effects and control strategies. Drugs Today (Barc) 2008, 44:895-904.
3. Leone A. Interactive effect of combined exposure to active and passive smoking on cardiovascular system. Recent Pat Cardiovasc Drug Discov 2011, 6:61-69.
4. Kolovou G.D., Mihas C., Kotanidou A., Dimoula Y., Karkouli G., Kadda O., Anagnostopoulou K., Mikhailidis D.P., Marvaki C. Mortality after first myocardial infarction in Greek patients: a 4-year follow-up study. Angiology 2009, 60(5):582-587.
5. Oberg M., Jaakkola M.S., Woodward A., Peruga A., Prüss-Ustün A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet 2011, 377:139-146.
6. Katsiki N., Hatzitolios A.I., Mikhailidis D.P. Passive smoking: the democratic right of nonsmokers to survive. Angiology 2011, 62(7):520-522.
7. Vardavas C.I., Panagiotakos D.B. The causal relationship between passive smoking and inflammation on the development of cardiovascular disease: a review of the evidence. Inflamm Allergy Drug Targets 2009, 8:328-333.
8. Ratchford E.V., Black J.H. Approach to smoking cessation in the patient with vascular disease. Curr Treat Options Cardiovasc Med 2011, 13:91-102.
9. Hall W., Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009, 374:1383-1391.
10. Mukamal K.J., Maclure M., Muller J.E., Mittleman M.A. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J 2008, 155:465-470.
11. Mittleman M.A., Lewis R.A., Maclure M., Sherwood J.B., Muller J.E. Triggering myocardial infarction by marijuana. Circulation 2001, 103:2805-2809.
12. Nawrot T.S., Perez L., Künzli N., Munters E., Nemery B. Public health importance of triggers of myocardial infarction: a comparative risk assessment. Lancet 2011, 377:732-740.
13. Thanvi B.R., Treadwell S.D. Cannabis and stroke: is there a link?. Postgrad Med J 2009, 85:80-83.
14. Tormey W. Adverse health effects of non-medical cannabis use. Lancet 2010, 375:196.
15. Vemuri V.K., Janero D.R., Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 2008, 93:671-686.
16. Mach F., Montecucco F., Steffens S. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk. Pharmacol Rep 2009, 61:13-21.
17. Kakafika A.I., Mikhailidis D.P., Karagiannis A., Athyros V.G. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007 May, 47(5):642-652.
18. Cahill K., Ussher M.H. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011, 3. CD005353.
19. Christopoulou F.D., Kiortsis D.N. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 2011, 36:10-18.
20. Le Foll B., Gorelick D.A., Goldberg S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009, 205:171-174.
21. Iribarren C. Reexamining health effects of cigar smoking: fashionable, but may increase the risk of coronary heart disease. Eur Heart J 2000, 21:505-506.
22. Shaper A.G., Wannamethee S.G., Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men. Int J Epidemiol 2003, 32:802-808.
23. Jacobs E.J., Thun M.J., Apicella L.F. Cigar smoking and death from coronary heart disease in a prospective study of US men. Arch Intern Med 1999, 159:2413-2418.
24. Håheim L.L., Holme I., Hjermann I., Leren P. Smoking habits and risk of fatal stroke: 18 years follow up of the Oslo Study. J Epidemiol Community Health 1996, 50:621-624.
25. Vlachopoulos C., Alexopoulos N., Panagiotakos D., O'Rourke M.F., Stefanadis C. Cigar smoking has an acute detrimental effect on arterial stiffness. Am J Hypertens 2004, 17:299-303.
26. Henley S.J., Thun M.J., Chao A., Calle E.E. Association between exclusive pipe smoking and mortality from cancer and other diseases. J Natl Cancer Inst 2004, 96:853-861.
27. Yatsuya H., Folsom A.R. ARIC Investigators. Risk of incident cardiovascular disease among users of smokeless tobacco in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2010, 172:600-605.
28. Maziak W. The global epidemic of waterpipe smoking. Addict Behav 2011, 36:1-5.
29. Cobb C., Ward K.D., Maziak W., Shihadeh A.L., Eissenberg T. Waterpipe tobacco smoking: an emerging health crisis in the United States. Am J Health Behav 2010, 34:275-285.
30. Neergaard J., Singh P., Job J., Montgomery S. Waterpipe smoking and nicotine exposure: a review of the current evidence. Nicotine Tob Res 2007, 9:987-994.
31. Shaikh R.B., Vijayaraghavan N., Sulaiman A.S., Kazi S., Shafi M.S. The acute effects of Waterpipe smoking on the cardiovascular and respiratory systems. J Prev Med Hyg 2008, 49:101-107.
32. Ramakrishnan S., Thangjam R., Roy A., Singh S., Ramakrishnan L., Seth S., Narang R., Bhargava B. Acute effects of tobacco chewing on the systemic, pulmonary and coronary circulation. Am J Cardiovasc Drugs 2011, 11:109-114. 10.2165/11586750-000000000-00000.
33. White W.B. Smoking-related morbidity and mortality in the cardiovascular setting. Prev Cardiol 2007, 10(2 Suppl. 1):1-4.
34. Henley S.J., Thun M.J., Connell C., Calle E.E. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005, 16:347-358.
35. Henley S.J., Connell C.J., Richter P., Husten C., Pechacek T., Calle E.E., Thun M.J. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 2007, 16(1):22-28.
36. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis 2009, 205:23-32.
37. Bolego C., Poli A., Paoletti R. Smoking and gender. Cardiovasc Res 2002, 53:568-576.
38. Harris B. The intractable cigarette 'filter problem'. Tob Control 2011, 20(Suppl. 1):i10-i16.
39. Doonan R.J., Hausvater A., Scallan C., Mikhailidis D.P., Pilote L., Daskalopoulou S.S. The effect of smoking on arterial stiffness. Hypertens Res 2010, 33:398-410.
40. Mackay D.F., Irfan M.O., Haw S., Pell J.P. Meta-analysis of the effect of comprehensive smoke-free legislation on acute coronary events. Heart 2010, 96:1525-1530.
41. Wilson K., Gibson N., Willan A., Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000, 160:939-944.
42. Lau J., Antman E.M., Jimenez-Silva J., Kupelnick B., Mosteller F., Chalmers T.C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992, 327:248-254.
43. Critchley J., Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004, (1). CD003041.
44. Hankey G.J. Smoking and risk of stroke. J Cardiovasc Risk 1999, 6:207-211.
45. Wannamethee S.G., Shaper A.G., Whincup P.H., Walker M. Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995, 274:155-160.
46. Shah R.S., Cole J.W. Smoking and stroke: the more you smoke the more you stroke. Expert Rev Cardiovasc Ther 2010, 8:917-932.
47. Streppel M.T., Boshuizen H.C., Ocké M.C., Kok F.J., Kromhout D. Mortality and life expectancy in relation to long-term cigarette, cigar and pipe smoking: the Zutphen Study. Tob Control 2007, 16:107-113.
48. Tverdal A., Bjartveit K. Health consequences of pipe versus cigarette smoking. Tob Control 2011, 20:123-130.
49. Wald N.J., Watt H.C. Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases. BMJ 1997, 314:1860-1863.
50. Wannamethee S.G., Lowe G.D., Shaper A.G., Rumley A., Lennon L., Whincup P.H. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005, 26:1765-1773.
51. Liapis C.D., Avgerinos E.D., Kadoglou N.P., Kakisis J.D. What a vascular surgeon should know and do about atherosclerotic risk factors. J Vasc Surg 2009, 49:1348-1354.
52. Conen D., Everett B.M., Kurth T., Creager M.A., Buring J.E., Ridker P.M., Pradhan A.D. Smoking, smoking cessation, and risk for symptomatic peripheral artery disease in women: a cohort study. Ann Intern Med 2011, 154(11):719-726.
53. Willigendael E.M., Teijink J.A., Bartelink M.L., Kuiken B.W., Boiten J., Moll F.L., Büller H.R., Prins M.H. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004, 40(6):1158-1165.
54. Planas A., Clará A., Marrugat J., Pou J.M., Gasol A., de Moner A., Contreras C., Vidal-Barraquer F. Age at onset of smoking is an independent risk factor in peripheral artery disease development. J Vasc Surg 2002, 35(3):506-509.
55. Lu J.T., Creager M.A. The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med 2004, 5:189-193.
56. Noël B., Ruf I., Panizzon R.G. Cannabis arteritis. J Am Acad Dermatol 2008, 58(Suppl. 1):S65-S67.
57. Almahameed A. Peripheral arterial disease: recognition and medical management. Cleve Clin J Med 2006, 73:621-626.
58. Paraskevas K.I., Stathopoulos V., Mikhailidis D.P., Perrea D. Smoking, abdominal aortic aneurysms, and ischemic heart disease: is there a link?. Angiology 2008 Dec-2009 Jan, 59:664-666.
59. Kakafika A.I., Mikhailidis D.P. Smoking and aortic diseases. Circ J 2007, 71:1173-1180.
60. Jamrozik K., Norman P.E., Spencer C.A., Parsons R.W., Tuohy R., Lawrence-Brown M.M., Dickinson J.A. Screening for abdominal aortic aneurysm: lessons from a population-based study. Med J Aust 2000, 173(7):345-350.
61. Wilmink T.B., Quick C.R., Day N.E. The association between cigarette smoking and abdominal aortic aneurysms. J Vasc Surg 1999, 30:1099-1105.
62. Lederle F.A., Johnson G.R., Wilson S.E., Chute E.P., Littooy F.N., Bandyk D., Krupski W.C., Barone G.W., Acher C.W., Ballard D.J. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997, 126(6):441-449.
63. Lederle F.A., Nelson D.B., Joseph A.M. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 2003, 38:329-334.
64. Golledge J., Muller J., Daugherty A., Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26:2605-2613.
65. Fitch K.V., Stavrou E., Looby S.E., Hemphill L., Jaff M.R., Grinspoon S.K. Associations of cardiovascular risk factors with two surrogate markers of subclinical atherosclerosis: endothelial function and carotid intima media thickness. Atherosclerosis 2011, 217(2):437-440.
66. Johnson H.M., Douglas P.S., Srinivasan S.R., Bond M.G., Tang R., Li S., Chen W., Berenson G.S., Stein J.H. Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study. Stroke 2007, 38(3):900-905.
67. Małecki R., Zdrojowy K., Adamiec R. Thromboangiitis obliterans in the 21st century - a new face of disease. Atherosclerosis 2009, 206:328-334.
68. Lawrence P.F., Lund O.I., Jimenez J.C., Muttalib R. Substitution of smokeless tobacco for cigarettes in Buerger's disease does not prevent limb loss. J Vasc Surg 2008, 48:210-212.
69. Paraskevas K.I., Liapis C.D., Briana D.D., Mikhailidis D.P. Thromboangiitis obliterans (Buerger's disease): searching for a therapeutic strategy. Angiology 2007, 58:75-84.
70. Brand F.N., Larson M.G., Kannel W.B., McGuirk J.M. The occurrence of Raynaud's phenomenon in a general population: the Framingham Study. Vasc Med 1997, 2:296-301.
71. Suter L.G., Murabito J.M., Felson D.T., Fraenkel L. Smoking, alcohol consumption, and Raynaud's phenomenon in middle age. Am J Med 2007, 120:264-271.
72. Pope J.E. The diagnosis and treatment of Raynaud's phenomenon: a practical approach. Drugs 2007, 67:517-525.
73. Paraskevas K.I., Hamilton G., Cross J.M., Mikhailidis D.P. Atherosclerotic renal artery stenosis: association with emerging vascular risk factors. Nephron Clin Pract 2008, 108:c56-c66.
74. Orth S.R. Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J Am Soc Nephrol 2004, 15(Suppl. 1):S58-S63.
75. Johnson D.W. Evidence-based guide to slowing the progression of early renal insufficiency. Intern Med J 2004, 34:50-57.
76. Voulgari C., Katsilambros N., Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 2011, 60(10):1456-1464.
77. Geddes C.C., Jardine A.G. Diagnosis and treatment of atherosclerotic renal artery stenosis (ARAS). Minerva Urol Nefrol 2002, 54:29-36.
78. Tsiara S., Elisaf M., Mikhailidis D.P. Influence of smoking on predictors of vascular disease. Angiology 2003, 54:507-530.
79. Paraskevas K.I., Bessias N., Papas T.T., Gekas C.D., Andrikopoulos V., Mikhailidis D.P. Do different vascular risk factors affect all arteries equally?. Angiology 2008, 59:397-401.
80. Nakamura K., Barzi F., Lam T.H., Huxley R., Feigin V.L., Ueshima H., Woo J., Gu D., Ohkubo T., Lawes C.M., Suh I., Woodward M. Asia Pacific Cohort Studies Collaboration. Cigarette smoking, systolic blood pressure, and cardiovascular diseases in the Asia-Pacific region. Stroke 2008, 39(6):1694-1702.
81. Al-Delaimy W.K., Manson J.E., Solomon C.G., Kawachi I., Stampfer M.J., Willett W.C., Hu F.B. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med 2002, 162(3):273-279.
82. Al-Delaimy W.K., Willett W.C., Manson J.E., Speizer F.E., Hu F.B. Smoking and mortality among women with type 2 diabetes: the Nurses' Health Study cohort. Diabetes Care 2001, 24:2043-2048.
83. Girach A., Manner D., Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006, 60:1471-1483.
84. Ayodele O.E., Alebiosu C.O., Salako B.L. Diabetic nephropathy - a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 2004, 96:1445-1454.
85. Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003, 45:405-413.
86. Chelland Campbell S., Moffatt R.J., Stamford B.A. Smoking and smoking cessation - the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 2008, 201:225-235.
87. Gepner A.D., Piper M.E., Johnson H.M., Fiore M.C., Baker T.B., Stein J.H. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. Am Heart J 2011, 161:145-151.
88. Willi C., Bodenmann P., Ghali W.A., Faris P.D., Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007, 298:2654-2664.
89. Gasparyan A.Y., Ayvazyan L., Mikhailidis D.P., Kitas G.D. Mean platelet volume: a link between thrombosis and inflammation?. Curr Pharm Des 2011, 17:47-58.
90. Avramakis G., Papadimitraki E., Papakonstandinou D., Liakou K., Zidianakis M., Dermitzakis A., Mikhailidis D.P., Ganotakis E.S. Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets 2007, 18(1):16-23.
91. Leone A. Smoking, haemostatic factors, and cardiovascular risk. Curr Pharm Des 2007, 13:1661-1667.
92. Daskalopoulou S.S., Daskalopoulos M.E., Mikhailidis D.P., Liapis C.D. Lipid management and peripheral arterial disease. Curr Drug Targets 2007, 8:561-570.
93. Honjo K., Iso H., Tsugane S., Tamakoshi A., Satoh H., Tajima K., Suzuki T., Sobue T. The effects of smoking and smoking cessation on mortality from cardiovascular disease among Japanese: pooled analysis of three large-scale cohort studies in Japan. Tob Control 2010, 19(1):50-57.
94. Pipe A.L., Eisenberg M.J., Gupta A., Reid R.D., Suskin N.G., Stone J.A. Smoking cessation and the cardiovascular specialist: Canadian Cardiovascular Society position paper. Can J Cardiol 2011, 27:132-137.
95. Youssef F., Gupta P., Mikhailidis D.P., Hamilton G. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology 2005, 56:279-287.
96. Milionis H.J., Rizos E., Mikhailidis D.P. Smoking diminishes the beneficial effect of statins: observations from the landmark trials. Angiology 2001, 52:575-587.
97. Hackshaw L., McEwen A., West R., Bauld L. Quit attempts in response to smoke-free legislation in England. Tob Control 2010, 19:160-164.
98. Miller L.S., Max W., Sung H.Y., Rice D., Zaretsky M. Evaluation of the economic impact of California's Tobacco Control Program: a dynamic model approach. Tob Control 2010, 19(Suppl. 1):i68-i76.
99. Li R., Zhang P., Barker L.E., Chowdhury F.M., Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010, 33:1872-1894.
100. Jiang Y., Elton-Marshall T., Fong G.T., Li Q. Quitting smoking in China: findings from the ITC China Survey. Tob Control 2010, 19(Suppl. 2):i12-i17.
101. Gardner B., West R. Public support in England for raising the price of cigarettes to fund tobacco control activities. Tob Control 2010, 19:331-333.
102. Bogdanovica I., Godfrey F., McNeill A., Britton J. Smoking prevalence in the European Union: a comparison of national and transnational prevalence survey methods and results. Tob Control 2011, 20:e4.
103. Elton-Marshall T., Fong G.T., Zanna M.P., Jiang Y., Hammond D., O'Connor R.J., Yong H.H., Li L., King B., Li Q., Borland R., Cummings K.M., Driezen P. Beliefs about the relative harm of "light" and "low tar" cigarettes: findings from the International Tobacco Control (ITC) China Survey. Tob Control 2010, 19(Suppl 2):i54-i62.
104. Murukutla N., Turk T., Prasad C.V., Saradhi R., Kaur J., Gupta S., Mullin S., Ram F., Gupta P.C., Wakefield M. Results of a national mass media campaign in India to warn against the dangers of smokeless tobacco consumption. Tob Control 2012, 21(1):12-17.
105. Teo K.K., Ounpuu S., Hawken S., Pandey M.R., Valentin V., Hunt D., Diaz R., Rashed W., Freeman R., Jiang L., Zhang X., Yusuf S. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006, 368(9536):647-658. INTERHEART Study Investigators.